USANA Health Sciences (USNA) Projected to Post Quarterly Earnings on Tuesday

Key Points

• USANA Health Sciences is set to announce its Q3 2025 earnings on October 21, with analysts predicting $0.47 EPS and $224.97 million in revenue.
• The company's market cap stands at $381.11 million, with shares trading at $20.86, a 1.6% increase for the day.
• Recent analyst ratings include a downgrade from "buy" to "hold" from Wall Street Zen, and a sell rating from Weiss Ratings, reflecting cautious sentiment among analysts.

USANA Health Sciences (NYSE:USNA - Get Free Report) is expected to be announcing its Q3 2025 results after the market closes on Tuesday, October 21st. Analysts expect the company to announce earnings of $0.47 per share and revenue of $224.9740 million for the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS.Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 22, 2025 at 11:00 AM ET.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share (EPS) for the quarter. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%.The business had revenue of $200.22 million during the quarter. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Stock Up 1.6%

Shares of NYSE USNA traded up $0.33 during trading on Tuesday, reaching $20.86. The company had a trading volume of 53,150 shares, compared to its average volume of 171,617. USANA Health Sciences has a 12-month low of $19.88 and a 12-month high of $41.83. The stock has a market cap of $381.11 million, a PE ratio of 11.52, a P/E/G ratio of 0.64 and a beta of 0.61. The business's 50-day moving average is $29.46 and its 200 day moving average is $29.26.

Analyst Ratings Changes

A number of equities research analysts have recently commented on USNA shares. Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of USANA Health Sciences in a research report on Wednesday, October 8th. Finally, Zacks Research cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, USANA Health Sciences currently has an average rating of "Reduce" and an average target price of $36.00.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total value of $106,363.90. Following the transaction, the insider owned 9,260 shares of the company's stock, valued at approximately $280,207.60. This represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert A. Fuller sold 1,058 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. 0.63% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. State of Wyoming raised its stake in shares of USANA Health Sciences by 48.1% in the second quarter. State of Wyoming now owns 7,725 shares of the company's stock worth $236,000 after buying an additional 2,509 shares during the period. Caxton Associates LLP bought a new stake in USANA Health Sciences during the 2nd quarter valued at approximately $202,000. Public Sector Pension Investment Board raised its stake in USANA Health Sciences by 5.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 36,851 shares of the company's stock valued at $1,125,000 after purchasing an additional 1,788 shares during the period. Tower Research Capital LLC TRC raised its stake in USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock valued at $73,000 after purchasing an additional 1,901 shares during the period. Finally, Vident Advisory LLC bought a new stake in USANA Health Sciences during the 2nd quarter valued at approximately $437,000. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.